These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9469265)

  • 1. Alanyl-aminopeptidase activity decrease in cerebrospinal fluid of Alzheimer patients.
    Iribar MC; Montes J; Gonzalez Maldonado R; Peinado JM
    Dement Geriatr Cogn Disord; 1998; 9(1):44-9. PubMed ID: 9469265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients.
    D'Aniello A; Fisher G; Migliaccio N; Cammisa G; D'Aniello E; Spinelli P
    Neurosci Lett; 2005 Nov; 388(1):49-53. PubMed ID: 16039064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer's disease.
    Molina JA; Jiménez-Jiménez FJ; Vargas C; Gómez P; de Bustos F; Ortí-Pareja M; Tallón-Barranco A; Benito-León J; Arenas J; Enríquez-de-Salamanca R
    J Neural Transm (Vienna); 1998; 105(2-3):279-86. PubMed ID: 9660106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid concentration in dementia of the Alzheimer type and multi-infarct dementia.
    Mochizuki Y; Oishi M; Hara M; Takasu T
    Ann Clin Lab Sci; 1996; 26(3):275-8. PubMed ID: 8726221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in cytosolic Aspartyl-aminopeptidase but not in Alanyl-aminopeptidase activity in the frontal cortex of the aged rat.
    Iribar C; Esteban MJ; Martinez JM; Peinado JM
    Brain Res; 1995 Jul; 687(1-2):211-3. PubMed ID: 7583308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer's disease and healthy control subjects.
    Basun H; Forssell LG; Almkvist O; Cowburn RF; Eklöf R; Winblad B; Wetterberg L
    J Neural Transm Park Dis Dement Sect; 1990; 2(4):295-304. PubMed ID: 2078309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease.
    Jiménez-Jiménez FJ; Molina JA; Gómez P; Vargas C; de Bustos F; Benito-León J; Tallón-Barranco A; Ortí-Pareja M; Gasalla T; Arenas J
    J Neural Transm (Vienna); 1998; 105(2-3):269-77. PubMed ID: 9660105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects.
    Fisher G; Lorenzo N; Abe H; Fujita E; Frey WH; Emory C; Di Fiore MM; D' Aniello A
    Amino Acids; 1998; 15(3):263-9. PubMed ID: 9871505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects.
    Fisher GH; Petrucelli L; Gardner C; Emory C; Frey WH; Amaducci L; Sorbi S; Sorrentino G; Borghi M; D'Aniello A
    Mol Chem Neuropathol; 1994; 23(2-3):115-24. PubMed ID: 7702702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective reduction of excitatory amino acids in cerebrospinal fluid of patients with Alzheimer type dementia compared with vascular dementia of the Binswanger type.
    Tohgi H; Abe T; Takahashi S; Kimura M
    Neurosci Lett; 1992 Jul; 141(1):5-8. PubMed ID: 1508400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia.
    Martinez M; Frank A; Diez-Tejedor E; Hernanz A
    J Neural Transm Park Dis Dement Sect; 1993; 6(1):1-9. PubMed ID: 8216758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease.
    Kaiser E; Schoenknecht P; Kassner S; Hildebrandt W; Kinscherf R; Schroeder J
    Neurodegener Dis; 2010; 7(4):251-9. PubMed ID: 20551690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls.
    Peskind ER; Leverenz J; Farlow MR; Ito RK; Provow SA; Siegel RS; Cleveland M; Morgan CH; Pandian MR; Corbin S; Nochlin D; Schellenberg GD; Raskind MA; Wagner SL
    Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):201-6. PubMed ID: 9437437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma renin-angiotensin system-regulating aminopeptidase activities are modified in early stage Alzheimer's disease and show gender differences but are not related to apolipoprotein E genotype.
    Puertas Mdel C; Martínez-Martos JM; Cobo M; Lorite P; Sandalio RM; Palomeque T; Torres MI; Carrera-González MP; Mayas MD; Ramírez-Expósito MJ
    Exp Gerontol; 2013 Jun; 48(6):557-64. PubMed ID: 23500679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease.
    Samakashvili S; Ibáñez C; Simó C; Gil-Bea FJ; Winblad B; Cedazo-Mínguez A; Cifuentes A
    Electrophoresis; 2011 Oct; 32(19):2757-64. PubMed ID: 21983823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
    Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease.
    Kuda T; Shoji M; Arai H; Kawashima S; Saido TC
    Biochem Biophys Res Commun; 1997 Feb; 231(3):526-30. PubMed ID: 9070837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.